Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

2(33.3%)

N/A

2(33.3%)

Phase 3

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 4(2)

N/A(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05228912Completed

Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.

Role: collaborator

NCT05252780Not ApplicableCompleted

A Community Dance Intervention Engaging Breast Cancer Survivors in a Middle-income Country

Role: collaborator

NCT04539873Phase 3Terminated

Impact of Colchicine in Hospitalized Colombian Patients With COVID-19

Role: collaborator

NCT04860544Completed

Is Red Blood Cell Transfusion a Risk Factor for Vascular Pedicle Thrombosis? The Study Case of a Latin American Cohort

Role: collaborator

NCT03704090Not ApplicableCompleted

Non-pharmacological Prevention of Postoperative Delirium by Occupational Therapy Teams

Role: collaborator

NCT04429763Phase 2Unknown

Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia

Role: collaborator

NCT02048293Phase 4Completed

Pharmacodynamic Differences Between Branded and Unbranded Remifentanil Molecules

Role: collaborator

NCT01746641Phase 4Terminated

Remifentanil Versus Propofol for TCI Sedation of Patients Undergoing Gastrointestinal Endoscopic Procedures

Role: collaborator

All 8 trials loaded